bevacizumab

Home
Ligands
bevacizumab

GtoPdb Ligand ID: 6771

Synonyms: Avastin® | rhuMAb-VEGF

bevacizumab is an approved drug (FDA (2004), EMA (2005))

Comment: Vascular endothelial growth factor A inhibitor.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars: Amgen's bevacizumab-awwb (Mvasi®) was the first bevacizumab biosimilar to be FDA approved. This and others are listed in the table below.

Name	Trade name	Company	Clinical Phase	Indications
bevacizumab-awwb	Mvasi	Amgen	Approved (FDA 2017)	Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney and cervical cancers.
bevacizumab-bvzr; PF-06439535	Zirabev	Pfizer	Approved (EMA & FDA 2019)	Approved to treat a range of cancers, including certain colorectal, lung, brain, kidney, cervical and breast cancers, plus recurrent glioblastoma (FDA).
SB8	Aybintio	Samsung Bioepis	Approved (EMA 2020)	Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
FKB238	Equidacent	Centus Biotherapeutics	Approved (EMA 2020)	Approved to treat a range of advanced solid tumour types, in combination with a number of chemotherapeutic drugs.
bevacizumab; MYL-1402O	Abevmy	Mylan	Approved (EMA 2021)	As per originator reference product.
bevacizumab-maly; BEVZ92-MB02	Oyavas; Alymsys	STADA Arzneimittel/Amneal//mAbxience	Approved (EMA 2021; FDA 2022)	As per originator reference product: NOT adjuvant treatment of colon cancer
bevacizumab	Onbevzi	Samsung Bioepis/Biogen	Approved (EMA 2021)	As per originator reference product
bevacizumab-adcd; CT-P16	Vegzelma	Celltrion	Approved (EMA & FDA 2022)	Approved to treat a range of advanced solid tumours in combination with other cancer drugs: Colorectal, breast, ovarian, fallopian tube, peritoneal, and uterine neoplasms, non-small cell lung cancer, and renal cell carcinoma
bevacizumab-tnjn; BAT1706	Avzivi	Bio-Thera Solutions	Approved (FDA 2023)	Approved for use in the treatment of advanced lung and colorectal cancers

References
1. Baca M, Chen Y M-Y, Lowman HB, Presta LG, Wells JA. (1998) Anti-vegf antibodies. Patent number: WO1998045331. Assignee: Genentech Inc,. Priority date: 07/04/1997. Publication date: 15/10/1998.
2. FDA. FDA approves bevacizumab in combination with chemotherapy for ovarian cancer. Accessed on 18/06/2018. Modified on 18/06/2018. fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610664.htm?utm_campaign=Oncology%206%2F13%2F2018&utm_medium=email&utm_source=Eloqua&elqTrackId=aedf1123feb446ac8126d28a2d6ce8d7&elq=7a1e38bda6884f40bcc462e71a154a89&elqaid=3898&elqat=1&elqCampaignId=3025
3. Glade-Bender J, Kandel JJ, Yamashiro DJ. (2003) VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther, 3 (2): 263-76. [PMID:12662141]
4. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. (2016) Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol, 27 (1): 114-21. [PMID:26487588]
5. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med, 349 (5): 427-34. [PMID:12890841]

References

1. Baca M, Chen Y M-Y, Lowman HB, Presta LG, Wells JA. (1998)
Anti-vegf antibodies.
Patent number: WO1998045331. Assignee: Genentech Inc,. Priority date: 07/04/1997. Publication date: 15/10/1998.

2. FDA.
FDA approves bevacizumab in combination with chemotherapy for ovarian cancer.
Accessed on 18/06/2018. Modified on 18/06/2018. fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm610664.htm?utm_campaign=Oncology%206%2F13%2F2018&utm_medium=email&utm_source=Eloqua&elqTrackId=aedf1123feb446ac8126d28a2d6ce8d7&elq=7a1e38bda6884f40bcc462e71a154a89&elqaid=3898&elqat=1&elqCampaignId=3025

3. Glade-Bender J, Kandel JJ, Yamashiro DJ. (2003)
VEGF blocking therapy in the treatment of cancer.
Expert Opin Biol Ther, 3 (2): 263-76. [PMID:12662141]

4. Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. (2016)
Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.
Ann Oncol, 27 (1): 114-21. [PMID:26487588]

5. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. (2003)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
N Engl J Med, 349 (5): 427-34. [PMID:12890841]